Leave Your Message
The 2026 market for Intermediate Of Balosevir deserves careful review, especially as buyers compare suppliers, grades, and regional prices. Balosevir is commonly associated with baloxavir-related pharmaceutical development, but terminology can vary across catalogs and technical documents. This difference matters. A misplaced letter may create confusion during supplier screening.
Dr. Takao Noshi, a Shionogi researcher associated with baloxavir development, has emphasized a principle relevant to procurement: “Quality consistency is the foundation of reliable antiviral development.” This statement captures the practical issue behind supplier selection. A low quoted price means little without batch records, identity testing, impurity profiles, residual-solvent data, and a clear certificate of analysis. Buyers should also check whether the material is research-grade, process-grade, or supported by manufacturing controls suitable for regulated development.
Price is rarely fixed. Order volume, purity, packaging, synthesis route, delivery region, and documentation can change the final quotation. Lead time matters too. A supplier offering ten-day dispatch may appear attractive, yet incomplete analytical files can delay internal approval for weeks. That delay is often more expensive than the original price difference.
This guide compares leading 2026 suppliers through a practical lens. It considers transparency, technical support, consistency, and commercial responsiveness. Public listings are useful, but they are not complete evidence. Some prices may be indicative rather than firm. That limitation deserves attention. Buyers should request current quotations, recent batch data, and applicable compliance documents before making decisions. Reliable sourcing is not simply about finding the cheapest Intermediate Of Balosevir. It is about reducing uncertainty at every step.
Baloxavir Intermediate: Definition, CAS Data, and Pharmaceutical Applications
Baloxavir intermediate describes a synthesis-stage compound used to produce baloxavir-related pharmaceutical substances. The term is not fully standardized. Commercial catalogs may list protected fragments, advanced intermediates, or the active metabolite precursor. Baloxavir marboxil is commonly identified by CAS 1985606-14-1, while related intermediates require separate identity checks. A CAS number alone is not a quality certificate.
The finished molecule is converted in the body to an active form that inhibits influenza virus cap-dependent endonuclease. This mechanism supports early treatment development for influenza infections. The World Health Organization estimates 3–5 million severe influenza cases occur globally each year, with up to 650,000 respiratory deaths. That burden sustains demand for reliable antiviral manufacturing inputs. IQVIA industry analyses also show continued growth in specialty and respiratory medicines, although projections differ by geography and methodology.
Quality teams should review assay results, residual solvents, impurity profiles, stereochemical data, and batch traceability before comparing 2026 supplier prices. Small differences in purity can change downstream yield. They can also alter the cost of waste handling. Public market reports often provide broad price ranges, not transaction-level evidence. This is where buyers need caution. Supplier quotations may exclude analytical testing, packaging, customs, and stability studies. A lower headline price may therefore be misleading. HPLC and NMR records matter. So does reproducibility.
| Material Category | CAS Number | Chemical / Regulatory Description | Typical Application | Common Commercial Grade | Indicative 2026 Price Range* | Typical MOQ | Typical Lead Time | Key Purchasing Checks |
|---|---|---|---|---|---|---|---|---|
| Baloxavir marboxil reference material | 1985606-47-8 | The finished prodrug form of baloxavir used for analytical comparison and pharmaceutical development. | Method development, impurity profiling, stability studies, and formulation research. | Research or analytical reference grade; not automatically suitable for clinical or commercial manufacture. | USD 2,500–12,000/kg equivalent* | 1–100 g | 2–8 weeks | Identity, assay, related substances, residual solvents, water content, storage conditions, and documentation. |
| Baloxavir acid / active-metabolite reference material | 1985606-12-9 | The pharmacologically active acid metabolite generated from baloxavir marboxil after hydrolysis in vivo. | Pharmacokinetic testing, bioanalytical method validation, metabolite identification, and reference-standard work. | Analytical or research grade, generally supplied in small quantities. | USD 4,000–20,000/kg equivalent* | 10–100 mg | 3–10 weeks | Stereochemical purity, chromatographic purity, structure confirmation, certificate of analysis, and retest period. |
| Late-stage protected baloxavir intermediate | CAS assignment varies by structure and salt/solvate form | A process-specific advanced intermediate used before final coupling, deprotection, or prodrug formation. | Route optimization, process validation, scale-up, and manufacture of baloxavir-related materials. | Custom synthesis or non-compendial process grade. | USD 800–6,000/kg* | 100 g–5 kg | 4–12 weeks | Exact structural identity, stereochemistry, impurity profile, residual catalysts, scalability, and change-control procedures. |
| Mid-stage chiral intermediate | Usually route-specific; verify against the supplier specification | A chiral building block or protected fragment used to establish the required stereochemistry of the baloxavir molecular framework. | Commercial process development and preparation of late-stage intermediates. | Technical or process-development grade. | USD 250–2,000/kg* | 1–25 kg | 3–10 weeks | Enantiomeric purity, assay, reaction history, residual solvents, particle properties, and batch-to-batch consistency. |
| Early-stage aromatic or heterocyclic building block | Individual CAS number depends on the selected route | A commercially available starting material incorporated into the fluorinated heterocyclic or aromatic portion of the synthesis. | Laboratory research, route screening, and pilot-scale intermediate production. | Technical grade or synthetic-use grade. | USD 50–600/kg* | 5–100 kg | 2–8 weeks | CAS verification, purity, moisture sensitivity, hazardous-substance classification, packaging, and transport requirements. |
| Baloxavir-related impurity or degradation product | May be assigned or structure-dependent | A structurally related substance used to identify, quantify, and control process or degradation impurities. | HPLC/LC–MS method validation, forced-degradation studies, and regulatory impurity characterization. | Certified analytical reference material. | USD 500–10,000/g* | 1–100 mg | 4–14 weeks | Assigned value, purity by quantitative method, spectral data, traceability, stability statement, and uncertainty information. |
*Price note: The price bands are non-binding market estimates for 2026 planning purposes. Actual quotations vary according to quantity, purity, stereochemical specification, synthesis route, analytical package, regulatory requirements, delivery terms, and production scale. Public catalogs may quote small analytical quantities at prices that are not comparable with kilogram-scale procurement.
Important classification note: “Baloxavir intermediate” is not one single universally defined chemical substance. Late-stage and mid-stage intermediates are often process-specific and may not have a unique CAS number. Buyers should request the complete structure, stereochemical designation, specification, certificate of analysis, safety data sheet, and change-control information before qualification.
